Reflections on the Biotech Earnings Bonanza: LLY, NVO, GILD

A look at some of top names in biotech show that the sector is still growing and 2014 could be another banner year.

Feb 6, 2014 at 6:30PM

Biotech earnings season is now in full swing. As I highlighted in my last article, I think it's key to think globally in terms of the sector's growth prospects. So, without further ado, here is my take on three biopharmaceutical companies that reported earnings recently.

Lowered expectations at Eli Lilly
Eli Lilly (NYSE:LLY) is seeing revenues fall off a cliff along with its patents for Cymbalta and Evista. Although the company saw modest revenue growth in 2013 of 2%, Lilly's management confirmed that revenues will fall markedly this year because of increasing generic competition for Cymbalta.

Turning our attention to the fourth quarter of 2013, revenues fell 2% compared to a year ago, mostly due to a 38% drop in Cymbalta sales. This massive drop in Cymbalta revenues were offset, however, by higher than expected sales of other products, especially Cialis and Humalog.

Looking to 2014, Lilly believes earnings will drop somewhere around 34-36% this year, which was the range Wall Street was expecting. On a positive note, the company does have five product candidates under regulatory review and another eight clinical candidates in late-stage development. So, there is a chance that an approval could boost guidance sometime this year. That said, I wouldn't expect Lilly to continue its share buyback program at its current pace and a dividend cut isn't out of the realm of possibility.

Gilead Sciences beats fourth quarter estimates, low-balls 2014 guidance
Perhaps one of the most talked about stocks in biotech these days is Gilead Sciences (NASDAQ:GILD). Gilead announced earnings earlier this week, beating analysts' estimates of earnings per share by 5%. Analysts and investors alike, however, are a tad disappointed by the release after Gilead's management didn't provide guidance on the company's new hepatitis C drug Sovaldi.

Despite numerous attempts by analysts during the Q&A, management continually stonewalled questions on the matter, saying it's still "early days" there are "too many unknowns". That said, management did give investors some good news on the Sovaldi front by announcing a roughly 1% reduction in the effective tax rate for every billion dollars in sales.

Sans Sovaldi sales, Gilead still expects 2014 revenues to grow by a healthy 6.4% or about $700 million, mostly because of its growing HIV franchise. Management also announced an Aug. 6th PDUFA date for the company's experimental leukemia drug idelalisib, giving investors even more to look forward to this year.

Turning back to Sovaldi sales, analysts certainly weren't shy about their predictions for 2014 sales earlier in the day. Baird's Brian Skorney, in particular, suggested that Sovaldi sales could exceed $5 billion this year alone, and his sentiment was echoed by a handful of other firms.

Taking these estimates at face value and doing some rough back of the envelope calculations, $5 billion would boost Gilead's annual revenues around 50%. So, if you were wondering what all the fuss is about, there you have it. Now, we have to wait to see if these optimistic estimates pan out in the coming months.

Novo Nordisk misses estimates but still sees healthy growth
Danish biopharma Novo Nordisk's (NYSE:NVO) fourth quarter net profits missed analyst estimates by 3.3%, due in large part, to decreasing operating margins in some markets. Even so, the company saw stellar growth for its diabetes franchise, led by a 27% increase in Victoza sales. On the back of this strong quarterly and yearly performance, Novo's management has decided to increase its dividend by 25% and to initiate a new round of share buybacks this year.

Novo's management is not exactly resting on its laurels, however. Last December, the company filed applications in the U.S. and EU for Victoza as a potential treatment for obesity, with a focus on patients with Type 2 diabetes. In late-stage trials, patients saw an 8% average weight loss when taking Victoza, putting it ahead of Arena Pharmaceutical's Belviq but slightly behind VIVUS's Qsymia. Overall, there are a number of good reasons to keep Novo Nordisk on your radar this year.

Foolish earnings breakdown
My brief earnings survey paints a healthy picture for the sector going forward. Most companies are beating estimates and are increasing guidance for 2014. That said, Eli Lilly shows the dangers of the ongoing patent cliff, with its earnings expected to fall dramatically. Another key theme this earnings season is lower effective tax rates. Alexion and Gilead are both beneficiaries of lower taxes, and I expect this trend to spread across the sector as companies look for ways to combat pricing pressure driven by austerity measures. Overall, this earnings snapshot should impress upon you that demand for health care products is still growing, and large biotech companies will likely command a premium in terms of share price as a result.


Could this stock outperform even Gilead this year?
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

George Budwell owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers